|
Ajanta Pharma Ltd has posted a net profit of Rs. 245.77 crore during the first quarter of FY25, a growth of 18 per cent compared to the Rs. 208.12 crore net profit reported during the corresponding quarter of previous fiscal year.
Revenue from operations during the first quarter of the current fiscal grew 12.1 per cent to Rs. 1,144.92 crore as against Rs. 1,021.04 crore reported a year ago.
The EBITDA stood at Rs. 330 crore against Rs. 271 crore, with a 22 per cent growth. Cash flow from operations was Rs. 466 crore, and the free cash flow was Rs. 301 crore, said the company.
The US generic business reported a sales of Rs. 228 crore, with seven per cent growth compared to the same quarter of last year. During the quarter, the company received three Abbreviated New Drug Application (ANDA) final approvals and it has filed two ANDAs during the period. Out of 56 final ANDA approvals, the company has commercialised 46 products. The company also holds two tentative approvals and is awaiting US FDA approval for 21 ANDAs, it said.
The generic business in India reported 10 per cent growth to Rs. 353 crore, and as per IQVIA report for June 2024, the company grew 8.9 per cent as against Indian pharma market growth of 7.6 per cent, it claimed. The higher than IPM growth is contributed mainly by new launches, which was about 1.3 times of IPM, it added.
R&D expenses for the quarter were Rs. 51 crore, around 4.5 per cent of the revenue, and it was against Rs. 55 crore spent in the same quarter of last year, it added. For the past 5 financial years, the company has posted healthy revenue CAGR of 13 per cent and even stronger PAT CAGR of 15 per cent, it claimed.
|